Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | SCN4A | P35499 | 1/20 | 0.49 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.49 |
| ▸ | P2RX4 | Q99571 | 12/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 2/20 | 0.36 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | P2RX1 | P51575 | 3/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7968347 | 0.79 | RAB9A (0.41) | LMNATSHRMAPK1SCN4ASCN5A | |
| SCHEMBL3691734 | 0.74 | LMNA (0.55) | LMNATSHRMAPK1SCN4ASCN5A | |
| SCHEMBL5282257 | 0.71 | ALDH1A1 (0.40) | LMNATSHRMAPK1SCN4ASCN5A | |
| SCHEMBL5969695 | 0.68 | KDM4E (0.32) | LMNATSHRMAPK1SCN4ASCN5A | |
| SCHEMBL1822854 | 0.68 | BRD4 (0.41) | LMNATSHRKDM4EMEN1ALDH1A1 | |
| SCHEMBL9396593 | 0.68 | LMNA (0.34) | LMNATSHRMAPK1SCN4ASCN5A | |
| SCHEMBL7334709 | 0.68 | LMNA (0.47) | LMNATSHRMAPK1SCN4ASCN5A | |
| SCHEMBL4753850 | 0.67 | TSHR (0.50) | LMNATSHRMAPK1SCN4ASCN5A | |
| SCHEMBL7329883 | 0.67 | MAPT (0.41) | LMNATSHRMAPK1SCN4ASCN5A | |
| Carbamazepine SCHEMBL21639 | 0.66 | LMNA (1.00) | LMNATSHRMAPK1SCN4ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12357635-B2 | Nanocarriers and their processing for diagnostics and therapeutics | RHODE ISLAND HOSPITAL (US) | 2025-07-15 | — | — | US | disclosed |
| US-20240156853-A1 | IN VITRO AND IN VIVO INTRACELLULAR DELIVERY OF SIRNA VIA SELF-ASSEMBLED NANOPIECES | RHODE ISLAND HOSPITAL | 2024-05-16 | — | — | US | disclosed |
| US-11701379-B2 | In vitro and in vivo intracellular delivery of siRNA via self-assembled nanopieces | RHODE ISLAND HOSPITAL (US) | 2023-07-18 | — | — | US | disclosed |
| CN-106793970-B | Nanoparring agents for diagnosis and therapy and processing thereof | 罗得岛医院 | 2021-07-30 | — | — | CN | disclosed |
| US-20210023117-A1 | IN VITRO AND IN VIVO INTRACELLULAR DELIVERY OF SIRNA VIA SELF-ASSEMBLED NANOPIECES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-01-28 | — | — | US | disclosed |
| US-20200375991-A1 | NANOCARRIERS AND THEIR PROCESSING FOR DIAGNOSTICS AND THERAPEUTICS | RHODE ISLAND HOSPITAL | 2020-12-03 | — | — | US | disclosed |
| US-10555948-B2 | Nanocarriers and their processing for diagnostics and therapeutics | RHODE ISLAND HOSPITAL (US) | 2020-02-11 | — | — | US | disclosed |
| WO-2019191151-A1 | IN VITRO AND IN VIVO INTRACELLULAR DELIVERY OF SIRNA VIA SELF-ASSEMBLED NANOPIECES | RHODE ISLAND HOSPTIAL (US) | 2019-10-03 | — | — | WO | disclosed |
| US-20180193344-A1 | Nanocarriers And Their Processing For Diagnostics And Therapeutics | RHODE ISLAND HOSPITAL | 2018-07-12 | — | — | US | disclosed |
| US-9963683-B2 | Biocatalytic process for preparing eslicarbazepine and analogs thereof | CODEXIS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-20050026909-A1 | Method of treating lower urinary tract disorders | DYNOGEN, INC. | 2005-02-03 | — | — | US | disclosed |
| US-20050020577-A1 | Method of treating lower urinary tract disorders | DYNOGEN, INC. | 2005-01-27 | — | — | US | disclosed |
| US-6846823-B2 | Method of treating lower urinary tract disorders | DYNOGEN PHARMACEUTICALS, INC. (US) | 2005-01-25 | — | — | US | disclosed |
| US-20040248979-A1 | Method of treating lower urinary tract disorders | DYNOGEN PHARMACEUTICALS, INC. | 2004-12-09 | — | — | US | disclosed |
| US-20040213842-A1 | Methods of treating gastrointestinal tract disorders using sodium channel modulators | DYNOGEN PHARMACEUTICALS, INC. | 2004-10-28 | — | — | US | disclosed |
| US-20040209869-A1 | Method of treating lower urinary tract disorders | DYNOGEN PHARMACEUTICALS, INC. | 2004-10-21 | — | — | US | disclosed |
| US-20040209960-A1 | Methods of treating lower urinary tract disorders using sodium channell modulators | DYNOGEN PHARMACEUTICALS, INC. | 2004-10-21 | — | — | US | disclosed |
| WO-2004066990-A2 | METHODS OF TREATING LOWER URINARY TRACT DISORDERS USING SODIUM CHANNEL MODULATORS | DYNOGEN PHARMACEUTICALS, INC. (US) | 2004-08-12 | — | — | WO | disclosed |
| WO-2004066987-A2 | USE OF SODIUM CHANNEL MODULATORS FOR TREATING GASTROINTESTINAL TRACT DISORDERS | DYNOGEN PHARMACEUTICALS, INC. (US) | 2004-08-12 | — | — | WO | disclosed |
| WO-2003106414-A2 | METHOD OF PREPARING A 5H-DIBENZ[B,F]AZEPINE-5-CARBOXAMIDE | TARO PHARMACEUTICALS U.S.A., INC. (US) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248979-A1 | Method of treating lower urinary tract disorders | RYR2, CACNA1S, CACNA1D | LMNA 2184/4885TSHR 4197/4885MAPK1 4588/4885 |
| US-12357635-B2 | Nanocarriers and their processing for diagnostics and therapeutics | SYVN1, SSB, TNF | LMNA 379/4885TSHR 2826/4885MAPK1 4133/4885 |
| US-20180193344-A1 | Nanocarriers And Their Processing For Diagnostics And Therapeutics | SYVN1, SSB, TNF | LMNA 379/4885TSHR 2826/4885MAPK1 4133/4885 |
| US-11701379-B2 | In vitro and in vivo intracellular delivery of siRNA via self-assembled nanopieces | NFATC1, TRAF6, UACA | LMNA 415/4885TSHR 2583/4885MAPK1 2376/4885 |
| US-20210023117-A1 | IN VITRO AND IN VIVO INTRACELLULAR DELIVERY OF SIRNA VIA SELF-ASSEMBLED NANOPIECES | NFATC1, TRAF6, UACA | LMNA 415/4885TSHR 2583/4885MAPK1 2376/4885 |
| US-10555948-B2 | Nanocarriers and their processing for diagnostics and therapeutics | SYVN1, SSB, TNF | LMNA 379/4885TSHR 2826/4885MAPK1 4133/4885 |
| US-20040213842-A1 | Methods of treating gastrointestinal tract disorders using sodium channel modulators | SLC10A2, VIPR2, TRPV1 | LMNA 4296/4885TSHR 464/4885MAPK1 2919/4885 |
| US-20200375991-A1 | NANOCARRIERS AND THEIR PROCESSING FOR DIAGNOSTICS AND THERAPEUTICS | SYVN1, SSB, TNF | LMNA 379/4885TSHR 2826/4885MAPK1 4133/4885 |
| US-20050020577-A1 | Method of treating lower urinary tract disorders | HTR3A, HTR3B, HTR3C | LMNA 2576/4885TSHR 2265/4885MAPK1 4258/4885 |
| US-20040209869-A1 | Method of treating lower urinary tract disorders | HTR3A, HTR3B, MME | LMNA 2570/4885TSHR 2176/4885MAPK1 4184/4885 |
| US-20040209960-A1 | Methods of treating lower urinary tract disorders using sodium channell modulators | CACNA1G, CACNA1D, CACNA1B | LMNA 3106/4885TSHR 1920/4885MAPK1 3323/4885 |
| US-20050026909-A1 | Method of treating lower urinary tract disorders | HTR3A, HTR3B, HTR3C | LMNA 2576/4885TSHR 2265/4885MAPK1 4258/4885 |
| US-20240156853-A1 | IN VITRO AND IN VIVO INTRACELLULAR DELIVERY OF SIRNA VIA SELF-ASSEMBLED NANOPIECES | NFATC1, TRAF6, UACA | LMNA 415/4885TSHR 2583/4885MAPK1 2376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.